Improving the therapeutic window of glycosylated drug classes and the development of a novel, rapid, high throughput analytical methodology to streamline the drug development pathway.

生物治疗药物的开发是有风险和昂贵的，目前从实验室到床边的时间表估计为7-10年，成本为28亿美元。该项目利用Glythera的技术，该技术可以稳定糖基化特征，以增加生物利用度和治疗窗口，从而提高药物的疗效，并通过减少给药周期来改善患者护理。GlycoSelect将开发一种针对Glythera技术的高度特异性凝集素，作为分析开发和表征的支持和正交方法。由于这种快速方法可以在发现的任何时间点部署到临床开发计划，这将支持和显著的去风险药物开发工作。两家公司将通过进一步开发改进的药物类别和与已知分析方法的比较来证明其组合技术的价值，从而巩固其在药物开发中的重要性。

Development of biotherapeutics is risky and expensive with current timelines from bench to bedside being estimated at 7-10 years at a cost of $2.8bn. This project exploits Glythera’s technology which can stabilise glycosylation profiles to increase bioavailability and the therapeutic window to enhance the efficacy of the drug but also patient care through the reduction in dosing cycles. GlycoSelect will develop a highly specific lectin to Glythera’s technology as a supporting and orthogonal approach to analytical development and characterisation. Since this rapid methodology can be deployed during any point in the discovery through to the clinical development programme this would support and significant de-risk drug development efforts. Both companies will demonstrate the value of their combined technologies through the further development of improved drug classes and comparison to known analytical methods underpinning their importance in drug development.